Pierre Kerbrat

Rennes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 29, 2023

Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.

Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.

Journal: Journal of adolescent and young adult oncology

Published: November 09, 2019

French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies.

French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies.

Journal: Joint bone spine

Published: June 12, 2019

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.

Journal: Lancet (London, England)

Published: January 20, 2019

Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years.

Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years.

Journal: International journal of cancer

Published: October 19, 2018

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 13, 2018

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 15, 2017

Improved survival using specialized multidisciplinary board in sarcoma patients.

Improved survival using specialized multidisciplinary board in sarcoma patients.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 09, 2017

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 11, 2017

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 09, 2017

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 30, 2016

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.

Journal: NPJ breast cancer

Published: August 28, 2016

Showing 1-12 of 93

Last Updated: 09/26/2026